Case Questions for: John A. Quelch and Heather Beckham (2010)‚ “Metabical: Pricing‚ Packaging‚ and Demand Forecasting for a New Weight-Loss Drug‚” Harvard Business Case #: 4183‚ Harvard Business Publishing. Instructions for answering the below questions: * Provide your answers in form of a memo addressed to me. * Use a bullet format (use approximately one to two sentence per bullet). * Use approximately five to eight bullets per question (when appropriate). * You must
Premium Marketing Forecasting Price
1. How does Metabical compare to current weight-loss options? * It was the only prescription drug to achieve the FDA * No side effects * Moderate weight loss for overweight people not the obese like other weightloss drugs * Dual layer controlled realise formulation. First layer appetite suppressant‚ 2nd layer is the fat blocker. Low dose levels of chemicals‚ so doesn’t cause heart or liver diseases. 2. What are the pros and cons of the forecasting methods presented by Printup
Premium Obesity Weight loss
such as new fixed-pressure fire valves? Metabical: Pricing‚ Packaging and Demand Forecasting for a New Weight-Loss Drug (Rozman‚ Rugelj‚ Šivec‚ Vuković) e) How does Metabical compare to current weight-loss options? f) What are pros and cons of the forecasting methods presented by Pintup? How would you do it? Make your own forecasts. g) What considerations should be taken into account when making decisions about the package count? What package size would
Premium Sime Darby Case study Marketing
* Weight-loss drugs Market before Metabical * Prevailing Safety Concerns; limiting options for patients * No prescription-drug option for the overweight segment (BMI 25-30) * Many OTC drugs available for patients with BMI 30+ including FDA-approved ‘Alli’ but various negative side effects reported‚ e.g.‚ 30 liver damage cases in Alli & Xenical during ‘99-‘08 * Other solutions categorized as herbal or dietary supplements were not regulated by the FDA i.e.‚ safety not warranted
Premium Obesity Medicine Weight loss
1. What makes Metabical different from the other weight-loss products on the market? Medibical is the first FDA-approved prescription drug for the overweight segment (BMI 25-30). It is a low-dose formula that reduces stress on heart and liver functions. Metabical also contains a controlled-release feature that requires only one pill be taken per day which leads to better patient compliance. Participants experience dramatic weight loss with an average 26 pounds for BMI 28-30 and 15 pounds for BMI
Premium Obesity Nutrition Dieting
INDIVIDUAL CASE STUDY METABICAL: _POSITIONING & COMMUNICATIONS STRATEGY_ _FOR A NEW WEIGHT-LOSS DRUG_ Q1: WHAT IS THE DECISION-MAKING PROCESS FOR METABICAL? WHO IS INVOLVED IN THE PROCESS? Consumer research over the years has shown that shoppers often follow a relatively common shopping behavior for product purchase. In theory‚ a shopper is said to go through the following five stages as a process. In reality‚ sometimes the steps may be switched around or even left out‚ as not all consumers
Premium Obesity Medicine Weight loss
1. What is the decision-making process for Metabical? Who is involved in the process? Market research: investigating into the overall adult overweight situation in U.S. fand overweight population and consumers’ perception of the currently existed weight-loss drugs. Analyzing differential advantages: CSP should recognize the Metabical’s competitive factors first. Metabical is the first prescription drug approved by FDA and has less negative side effect and can magically loss weight. Recognizing
Premium Obesity Weight loss Health
Apparently it’s Printup the senior director of marketing who is assigned the task to make decisions about Metabical. These decisions about Metabical will decide the fate of the drug. If it is observed closely there are many other stakeholders involved that will eventually decide about the fate of this drug. Printup would decide the marketing and public relation strategies to push the drug in the market. But it’s FDA that’s quite active and concerned after few awful events which occurred from usage
Premium Marketing Decision making
Syllabus as of October 10‚ 2012 NYU/Stern Executive MBA Program B01.2310.87: Marketing Spring‚ 2013 Professor Priya Raghubir Office: Tisch 809; Phone: 212.998.0727; Fax: 212.995.4006 e-mail: raghubir@stern.nyu.edu; Web: www.stern.nyu.edu/~raghubir Course Objectives As the core Marketing course in the EMBA program‚ the objectives of this course are: 1. To introduce you to the role of marketing in organizations; 2. To teach the basic concepts and tools used in marketing‚ including: - Elements of
Premium Marketing Decision making Brand management
Overview Quelch and Beckham present a break down of the weight-loss product called “Metabical”. Quelch and Beckham show that “Metabicals” optimal target customer are Over Weight United States demographic. Premises “Excess weight is considered a public health crisis in the U.S.‚ with approximately 65% of the entire adult population categorized as overweight‚ obese‚ or severely obese.” True This premises supports the claim the question presents in showing evidence that authors of the case
Premium Obesity Hypertension Cancer